Loading...
•
Mar 31, 2023
Travere Q1 2023 Earnings Report
Reported first quarter financial results, highlighted by FILSPARI's FDA approval and commercial launch, and total net product sales of $50.3 million.
Key Takeaways
Travere Therapeutics reported a net product sales of $50.3 million for Q1 2023, including $3.0 million from FILSPARI. Total revenue reached $57.0 million, with $6.7 million from licensing and collaboration. The company's cash, cash equivalents, and marketable securities totaled $561.5 million as of March 31, 2023.
FILSPARI gained accelerated FDA approval for IgAN on February 17, 2023, and commercial launch is underway.
FILSPARI net product sales reached $3.0 million in Q1 2023.
Total revenue for Q1 2023 was $57.0 million, including $50.3 million in net product sales and $6.7 million in licensing and collaboration revenue.
Cash, cash equivalents, and marketable securities totaled $561.5 million as of March 31, 2023.
Revenue by Segment
Forward Guidance
Travere Therapeutics is focused on the continued progress of the FILSPARI launch and achieving additional development and regulatory milestones.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...